1. Bisdemethoxycurcumin has antioxidant activity.
2. Bisdemethoxycurcumin has antiedemic activity.
3. Bisdemethoxycurcumin has antitumour activity.
4. Bisdemethoxycurcumin has anti-inflammatory activity.
5. Bisdemethoxycurcumin inhibits PDGF-induced vascular smooth muscle cell motility and proliferation.
6. Bisdemethoxycurcumin inhibits LPS-induced nitric oxide (NO) production and expression of iNOS and COX2 in RAW264.7 cells by blocking NF-kB activation.
1. Coumarin is an edema modifier in clinical medical treatment.
2. Coumarin has appetite-suppressing properties, which in plants may reduce the impact of grazing animals.
3. Coumarin is also used as a gain medium in some dye lasers, and as a sensitizer in older photovoltaic technologies.
4. Coumarin is used in the pharmaceutical industry as a precursor reagent in the synthesis of a number of synthetic anticoagulant pharmaceuticals similar to dicoumarol.
1. Naringin inhibits some drug-metabolizing cytochrome P450 enzymes, including CYP3A4 and CYP1A2, which may result in drug-drug interactions.
2. Naringin has protective effects against cognitive dysfunction and reduces diabetes-induced neuropathy in rats.
3. Naringin is an inhibitor of vascular endothelial growth factor (VEGF) release, which causes angiogenesis.
4. Naringin has antioxidant properties in its cardioprotective effects in various models, by providing cardioprotection by inducing the phosphorylation of ERK1/2, PKCδ, and AKT, which subsequently activated Nrf2 and its downstream genes.
1. Dehydroabietic acid (DAA) is an EBV-EA activation inhibitor.
2. DAA is a useful food-derived compound for treating obesity-related diseases, by decreasing plasma glucose, insulin levels, plasma triglyceride (TG) ,and hepatic TG levels.
3. DAA derivatives displays anti-secretory and anti-pepsin effect in animal models.